3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
Lung Neoplasms
1
Interventions
Pemetrexed
39
Cisplatin
33
pembrolizumab
21
Nivolumab
17
Carboplatin
16
Ipilimumab
13
Gemcitabine
10
Cyclophosphamide
9
fludarabine
6
durvalumab
6
Bevacizumab
6
Radiotherapy, Intensity-Modulated
4
LMB-100
4
Dexamethasone
4
tremelimumab
3
tazemetostat
3
spartalizumab
3
olaparib
3
niraparib
3
atezolizumab
3
anetumab ravtansine
3
amatuximab
3
Vinorelbine
3
Paclitaxel
3
Imatinib Mesylate
3
Cerebral Decortication
3
tislelizumab
2
sargramostim
2
fludarabine phosphate
2
defactinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Mesothelioma
×
UV1 vaccine
×
Clear all
NCT04300244
2024-02-29
NIPU
Oslo University Hospital
Phase 2
Active not recruiting
118 enrolled